Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
23:58:26 EDT Wed 02 Jul 2025
Enter Symbol
or Name
USA
CA



Q:IPHA - INNATE PHARMA SPON ADS EACH REP 1 ORD SHS - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
IPHA - Q1.21.81·2.880.61.82-0.025-1.45.49231.85  1.8989  1.823.5107  1.2915:58:22Jun 1715 min RT 2¢

Recent Trades - Last 10 of 23
Time ETExPriceChangeVolume
15:58:22Q1.84680.001827
15:56:02Q1.82-0.0252
15:46:30Q1.82-0.0251
15:28:34Q1.82-0.02520
15:22:04Q1.82-0.02526
15:22:04Q1.82-0.025153
15:09:45Q1.82-0.02540
15:09:44Q1.83-0.01562
11:36:41Q1.850.0051
11:23:59Q1.850.005786

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-06-17 01:00U:IPHANews ReleaseInnate Pharma Announces Its Participation in H.C. Wainwright and Wolfe Research Healthcare Conferences
2025-06-13 01:00U:IPHANews ReleaseInnate Pharma Highlights Preclinical Antitumor Activity of IPH6501 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma at the 2025 European Hematology Association (EHA) Congress
2025-05-27 01:00U:IPHANews ReleaseInnate Pharma Announces Its Participation in Jefferies and Goldman Sachs Healthcare Conferences
2025-05-23 01:00U:IPHANews ReleaseInnate Pharma Highlights Durable Responses to Lacutamab in Sezary Syndrome and Mycosis Fungoides
2025-05-23 01:00U:IPHANews ReleaseOutcome of Innate Pharma's 2025 Annual General Meeting
2025-05-19 01:00U:IPHANews ReleaseInnate Pharma Highlights Abstracts Selected for ASCO 2025 Annual Meeting
2025-05-15 01:00U:IPHANews ReleaseInnate Pharma Highlights ANKET(TM) Abstracts Selected for the EHA 2025 Congress
2025-05-13 01:00U:IPHANews ReleaseInnate Pharma Reports First Quarter 2025 Business Update and Financial Results
2025-05-12 01:00U:IPHANews ReleaseNumber of Shares and Voting Rights of Innate Pharma as of May 5, 2025
2025-05-06 01:00U:IPHANews ReleaseInnate Pharma announces conference call and webcast for Q1 2025 business update
2025-04-30 11:30U:IPHANews ReleaseInnate Pharma Files Its 2024 Universal Registration Document (Document d'enregistrement universel) and 2024 Annual Report on Form 20-F
2025-04-29 15:00U:IPHANews ReleaseInnate Pharma Highlights Preclinical Anti-Tumor Efficacy Data of Its Antibody Drug Conjugate IPH4502 at the AACR 2025 Annual Meeting
2025-04-28 01:00U:IPHANews ReleaseNumber of Shares and Voting Rights of Innate Pharma as of April 25, 2025
2025-04-24 01:35U:IPHANews ReleaseInnate Pharma Announces euros15M Investment by Sanofi
2025-04-23 01:00U:IPHANews ReleaseInnate Pharma Regains Its Rights on CD123 Targeting ANKET(TM) and Announces Sanofi's Intention to Make a Strategic Investment in the Company
2025-04-16 01:00U:IPHANews ReleaseInnate Pharma Proposes to Its Shareholders to Transform Its Corporate Governance Structure Into a Board of Directors and to Change Its Composition
2025-04-16 01:00U:IPHANews ReleaseInnate Pharma to Hold Its Annual General Meeting of Shareholders on May 22, 2025
2025-04-03 01:00U:IPHANews ReleaseInnate Pharma to Participate in the 2025 Stifel Virtual Targeted Oncology Forum
2025-03-27 02:00U:IPHANews ReleaseInnate Pharma Reports Full Year 2024 Financial Results and Business Update
2025-03-26 02:00U:IPHANews ReleaseInnate Pharma Highlights Antibody Drug Conjugate IPH4502 Abstract Selected for the AACR 2025 Annual Meeting